Polyrizon Ltd. PLRZ
10.17 USD -0.86 (-7.84%)
Regular-session close
10.32 +0.15 +1.47%
After hours · Nov 19, 4:00 PM ET
10.17 Day range 11.25
2.88 52-week range 18.20
- YTD
- +19.74%
- 1 year
- +141.47%
News
globenewswire.com POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN TEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…benzinga.com Polyrizon Completes Participant Enrollment In Its Trial Of NASARIX To Treat Airborne Allergens Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced the successful
globenewswire.com Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker All 120 planned participants randomized across five clinical sites in the United States Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by…
globenewswire.com Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform A new patent application covers Polyrizon's proprietary mucoadhesive platform and its potential applications in nasal drug delivery.
globenewswire.com Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker First patient marks Polyrizon's transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker…
globenewswire.com Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd.
globenewswire.com Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement RAANANA, ISRAEL, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal…
globenewswire.com Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study Raanana, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative…
globenewswire.com Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd.…
globenewswire.com Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative…
globenewswire.com Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative…
globenewswire.com Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative…
globenewswire.com Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker's protective barrier…
globenewswire.com Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative…
globenewswire.com Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative…
globenewswire.com Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial Raanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative…
prnewswire.com Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection In light of the growing challenges posed by emerging respiratory threats, including recent Hantavirus, Polyrizon is advancing a biophysical barrier technology that may offer immediate, non-specific…
globenewswire.com Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform Raanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative…
globenewswire.com Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative…
globenewswire.com Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements RAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today…
globenewswire.com Polyrizon Provides 2025 and Recent Highlights Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and…
